Theriva Biologics, Inc. 8-K

What Happened

• Theriva Biologics, Inc. announced that its Special Meeting of Stockholders called on February 11, 2026 could not be convened because there were not enough shares present or represented by proxy to constitute a quorum.
• The meeting was intended to seek stockholder approval of the exercise/issuance of common stock purchase warrants (the “New Warrants”) as described in the definitive proxy filed January 5, 2026. The company will announce and mail proxy materials for a new meeting date.

Key Details

• Special Meeting date: February 11, 2026 — meeting did not achieve a quorum.
• Warrant/approval involved: up to 16,184,560 shares of common stock issuable upon exercise of New Warrants.
• Relevant agreements/dates: Inducement Agreement dated October 16, 2025; definitive proxy statement filed January 5, 2026.
• Next steps required: Under the Inducement Agreement, Theriva must use reasonable best efforts to call a stockholder meeting within 60 days following the closing and, because the meeting did not convene, must call additional meetings every 60 days thereafter (unless investors waive the requirement) until stockholder approval is obtained or the New Warrants are no longer outstanding.

Why It Matters

• Investors should note the potential dilution: approval would allow issuance of up to 16,184,560 new shares if the New Warrants are exercised, which could dilute existing shareholders’ ownership.
• Repeated meetings (every 60 days) can delay final approval, increase administrative costs, and prolong uncertainty about whether and when those shares may be issued.
• The company will provide a new meeting date and mail updated proxy materials; shareholders should watch for those filings and any related disclosures.